Without plasma exchange TTP can be rapidly fatal, and the clinician needs to be certain that a deficiency of ADAMTS13 is not the cause of the TMA before plasma exchange can be withdrawn and eculizumab is initiated. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.